New Haven: The Next Level in Pulmonary Care

Activity Info

The Next Level in Pulmonary Care: What YOU Need to Know in 2019
Friday, September 20 • 7:30 am–4:00 pm
Omni New Haven Hotel at Yale

Omni New Haven Hotel at Yale
155 Temple Street
New Haven, CT 06510
7:30 AM – 4:00 PM
Download Meeting Agenda >> (PDF 0.2 MB)


Personalized education for pulmonologists, radiologists, primary care physicians, respiratory therapists, nurses, physician assistants, pharmacists, and palliative care physicians.

Create your own schedule and choose from topics including Interstitial Lung Disease, Asthma, and COPD. Sessions include education on:

• Optimizing Patient Outcomes

• Palliative Medicine

• Thoracic Radiology

• Everyday Breathing Challenges

• Rare Diseases

• Adherence and Side Effects

• Developing an Action Plan

This activity is supported by independent educational grants from Actelion Pharmaceuticals US, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Genentech and Mallinckrodt Pharmaceuticals.

Target Audience
This activity will target community pulmonologists, radiologists, primary care (internal and family medicine), respiratory nurses, advanced practice providers (nurse practitioners and physician assistants), specialty pharmacists, palliative care physicians, and other health care providers who are involved in the management of patients with pulmonary various diseases.

Overall Activity Objectives:


  • Use a multidisciplinary approach based on ATS/ERS guidelines for diagnosing IPF
  • Incorporate new findings/recommendations into the diagnostic process for IPF
  • Recognize signs and symptoms that may indicate IPF
  • Provide rationales for starting treatment
  • Provide rationales for switching treatment
  • Use strategies for mitigating IPF treatment side effects and increasing adherence
  • Address IPF comorbidities


  • Perform a thorough assessment of asthma severity and control in day-to-day practice.
  • Explain how mechanisms of action of new/emerging Type 2 inflammation-directed treatments address the underlying immunology of asthma.
  • Select appropriate Type 2 inflammation-targeted therapies on the basis of safety and efficacy data, and phenotype.


  • Choose diagnostic interventions (including consultations with other specialties) that can help confirm the necessary diagnosis of exclusion for sarcoidosis.


Pulmonary | MOC | CME (AMA PRA Category 1 Credit) | Live | Allergy/Clinical Immunology | Radiology | Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease | Asthma | PILOTforPulmonary.org | Live Event | ACPE |